You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
宜明昂科-B(01541.HK):IMM0306治療視神經脊髓炎譜系疾病的IB期臨牀試驗完成首例患者給藥
格隆匯 12-17 18:04

格隆匯12月17日丨宜明昂科-B(01541.HK)發佈公吿,IMM0306(一種靶向CD47xCD20的原創新藥雙特異性抗體)治療視神經脊髓炎譜系疾病(NMOSD)的Ib期臨牀試驗成功完成首例患者給藥,且並無不良事件報吿。

由集團獨立研發的IMM0306是一種靶向分化簇47(CD47)及分化簇20(CD20)的雙特異性分子,是全球首個進入臨牀階段的CD47和CD20雙靶向雙特異性分子。IMM0306透過抑制CD47-SIRPα相互作用來阻斷「別吃我」訊號,增強Fc-FcɣRIIa和Fc-FcɣRIIIa相互作用來激活巨噬細胞和NK細胞,並優先結合CD20而非CD47,以有效消除惡性B細胞,同時將毒性降至最低,從而可改善治療效果。

截至本公吿日期,集團擁有IMM0306的全球知識產權及商業化權利。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account